Diffusion Pharmaceuticals Inc. (DFFN)
$4.4
+0.41 (+10.28%)
Rating:
Recommendation:
Neutral
| Symbol | DFFN |
|---|---|
| Price | $4.4 |
| Beta | 1.764 |
| Volume Avg. | 0.05M |
| Market Cap | 8.977M |
| Shares () | - |
| 52 Week Range | 4.139999-14.37 |
| 1y Target Est | - |
| DCF Unlevered | DFFN DCF -> | |
|---|---|---|
| DCF Levered | DFFN LDCF -> | |
| ROE | -44778.86% | Strong Sell |
| ROA | -53338.28% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -0.62 | |
| P/B | 0.63 | Buy |
Latest DFFN news
About
Download (Excel)Dr. Robert J. Cobuzzi Jr., Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.